Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | PKM | P14618 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14837977 | 0.82 | CYP17A1 (0.50) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 | |
| SCHEMBL14830687 | 0.80 | CYP17A1 (0.32) | CYP1A2 | |
| SCHEMBL14830565 | 0.77 | CYP17A1 (0.50) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 | |
| SCHEMBL8121980 | 0.75 | ESR1 (0.49) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 | |
| SCHEMBL29652541 | 0.75 | ESR1 (0.49) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 | |
| SCHEMBL26349681 | 0.75 | CYP1A2 (0.45) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 | |
| SCHEMBL14830642 | 0.73 | CYP17A1 (0.49) | TP53SMN1; SMN2NPC1HSD17B10MAPT | |
| SCHEMBL14830942 | 0.73 | KDM4E (0.49) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 | |
| SCHEMBL7890686 | 0.72 | LRRK2 (0.44) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 | |
| SCHEMBL14830689 | 0.72 | CYP17A1 (0.72) | TP53SMN1; SMN2NPC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| EP-2760870-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049263-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049263-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP1A2, CYP3A43, CYP4A22 | TP53 707/4885SMN1; SMN2 3722/4885NPC1 768/4885 |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | TP53 626/4885SMN1; SMN2 3942/4885NPC1 739/4885 |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | TP53 626/4885SMN1; SMN2 3942/4885NPC1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.